Disitamab Vedotin
HER2 Positive Breast Carcinoma
Fudan Universityantibody_drug_conjugatePhase 4 / ApprovedActive
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 63/ 100
- Competitive Position
- 65/ 100
Competitive context
175 Active assets in the HER2 Positive Breast Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pertuzumab SWOG Cancer Research Network | Phase 4 | BB |
Trastuzumab SWOG Cancer Research Network | Phase 4 | BB |
Ribociclib Danish Breast Cancer Cooperative Group | Phase 3 | BB |
Capecitabine MedSIR | Phase 4 | BB |
Vinorelbine Ditartrate Fudan University | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Disitamab Vedotin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →